阴沟肠杆菌
微生物学
生物
肠杆菌科
抗药性
亚胺培南
肠杆菌
美罗培南
抗生素耐药性
他唑巴坦
碳青霉烯
病毒学
头孢菌素
大肠杆菌
哌拉西林
厄他培南
作者
Dennis Nurjadi,Kaan Kocer,Quan Chanthalangsy,Sabrina Klein,Klaus Heeg,Sébastien Boutin
摘要
Cefiderocol is a promising novel siderophore cephalosporin for the treatment of multi-drug resistant Gram-negative bacilli and with stability against degradation by metallo-β-lactamases. Nonetheless, the emergence of cefiderocol in metallo-β-lactamase-producing Enterobacterales during therapy has been reported on more than one occasion. To understand the underlying mechanisms and factors facilitating the resistance development, we conducted an in vitro evolution experiment using clinical E. cloacae isolates via serial passaging under cefiderocol pressure. In this study, we show that the presence of the New-Delhi metallo-β-lactamase (NDM) facilitates the emergence of resistance via non-synonymous mutations of the CirA catecholate siderophore receptor. Inhibition of metallo-β-lactamase activity using dipicolinic acid prevented the emergence of cefiderocol-resistant mutants successfully. This finding implies that caution should be taken, when using cefiderocol for the treatment of infections caused by metallo-β-lactamase- producing bacteria.
科研通智能强力驱动
Strongly Powered by AbleSci AI